Skip to main content

Table 1 Baseline demographic and laboratory data

From: Usefulness of glycated albumin as a predictor of mortality in chronic hemodialysis patients with diabetes: a multi-center, prospective cohort study

 

Overall (n = 841)

Age

64 ± 11 years

Men

606 (72.1%)

Dialysis vintage

4.5 years (2.4–7.9)

Type 1 diabetes

75 (8.9%)

Diabetes therapy

 Insulin

344 (40.9%)

 Other medication

369 (43.9%)

 ACE inhibitors or ARBs

552 (65.6%)

 Other antihypertensive drugs

600 (71.3%)

 Statins

272 (32.3%)

 History of ASCVD

333 (39.6%)

 Current smoker

168 (20.0%)

 Body mass index

23.5 ± 4.0 kg/m2

 SBP

154 ± 23 mmHg

 DBP

78 ± 13 mmHg

Laboratory data

 GA

21.4 ± 5.0%

 HbA1c

6.4 ± 1.1%

 Glucose

145 ± 55 mg/dL

 Hemoglobin

10.8 ± 1.1 g/dL

 Albumin

3.6 ± 0.3 g/dL

 Urea nitrogen

59.3 ± 15.2 mg/dL

 Creatinine

10.5 ± 2.6 mg/dL

 Potassium

4.9 ± 0.7 mEq/L

 Corrected calcium

9.5 ± 0.7 mg/dL

 Phosphate

5.6 ± 1.4 mg/dL

 HDL cholesterol

45 ± 15 mg/dL

 Non-HDL cholesterol

109 ± 32 mg/dL

  1. Data are expressed as mean (standard deviation), median (interquartile range), or number (percentage)
  2. ACE angiotensin-converting enzyme, ARBs angiotensin receptor blockers, ASCVD atherosclerotic cardiovascular disease, SBP systolic blood pressure, DBP diastolic blood pressure, GA glycated albumin, HbA1c hemoglobin A1c, HDL high-density lipoprotein